Search Results - "Magnano, Antonio"
-
1
LncRNA UCA1, Upregulated in CRC Biopsies and Downregulated in Serum Exosomes, Controls mRNA Expression by RNA-RNA Interactions
Published in Molecular therapy. Nucleic acids (07-09-2018)“…Long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) contribute to the onset of many neoplasias through RNA-RNA competitive interactions; in addition,…”
Get full text
Journal Article -
2
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis
Published in Digestive and liver disease (01-12-2018)“…Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis. We reported the comparative effectiveness of adalimumab and…”
Get full text
Journal Article -
3
Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases
Published in JGH open (01-03-2021)“…Background and Aim Ustekinumab is approved in Europe for the treatment of moderate to severe Crohn's disease (CD). Italian real‐life data are scarce, so the…”
Get full text
Journal Article -
4
Solitary hemangioma of the small intestine: an unusual cause of bleeding diagnosed at capsule endoscopy
Published in Journal of pediatric surgery (01-10-2005)“…Solitary small intestine hemangiomas are rare and usually present with overt bleeding or chronic anemia. Diagnosis is usually difficult because traditional…”
Get full text
Journal Article -
5
Clinical Challenges and Images in GI
Published in Gastroenterology (New York, N.Y. 1943) (01-04-2008)Get full text
Journal Article -
6
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19
Published in Inflammatory bowel diseases (01-02-2023)“…Abstract Background Data from the first wave of the coronavirus disease 2019 (COVID-19) pandemic suggested that patients with inflammatory bowel disease (IBD)…”
Get full text
Journal Article -
7
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501
Published in Journal of gastroenterology and hepatology (01-11-2021)“…Background and Aim There are few clinical data on Adalimumab (ADA) biosimilars in inflammatory bowel disease. We aimed to perform a multicenter, observational,…”
Get full text
Journal Article -
8
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases
Published in Digestive and liver disease (01-07-2018)“…The effectiveness of vedolizumab in real-world practice is under evaluation, while its role in inflammatory bowel disease-associated spondyloarthritis is still…”
Get full text
Journal Article -
9
-
10
-
11
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches
Published in Inflammatory bowel diseases (19-01-2021)“…Abstract Background No data on the recently introduced infliximab (IFX) biosimilar SB2 in inflammatory bowel disease (IBD) are available. Methods The Sicilian…”
Get full text
Journal Article -
12
Un ricordo familiare
Published in SocietàMutamentoPolitica (Firenze) (01-03-2021)Get full text
Journal Article -
13
Un ricordo familiare
Published in SocietàMutamentoPolitica (Firenze) (01-03-2021)Get full text
Journal Article -
14
Efficacy of 1 L polyethylene glycol plus ascorbate versus 4 L polyethylene glycol in split-dose for colonoscopy cleansing in out and inpatient: A multicentre, randomized trial (OVER 2019)
Published in Digestive and liver disease (01-03-2024)“…Adequate bowel cleansing is essential for colonoscopy quality. A novel 1 L polyethylene glycol plus ascorbate (1 L PEG+ASC) solution has been recently…”
Get full text
Journal Article -
15
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis
Published in Digestive and liver disease (01-12-2020)“…No real-life study on the comparative effectiveness of Vedolizumab (VDZ), Adalimumab (ADA), and Golimumab (GOL) in ulcerative colitis (UC) is currently…”
Get full text
Journal Article -
16
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
Published in Drugs & aging (01-05-2020)“…Background and Objective Older people with inflammatory bowel disease (IBD) appear to have a lower response to anti-tumour necrosis factor (TNF) therapy, with…”
Get full text
Journal Article -
17
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease
Published in Digestive and liver disease (01-05-2022)“…The role of Vedolizumab (VDZ) as therapeutic option for the postoperative recurrence of Crohn's disease (CD) following ileocolonic resection is unknown. To…”
Get full text
Journal Article -
18
Letter: SPOSIB SB2—a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2
Published in Alimentary pharmacology & therapeutics (01-01-2019)“…Linked ContentThis article is linked to Schmitz et al paper. To view these articles, visit https://doi.org/10.1111/apt.14453…”
Get full text
Journal Article -
19
-
20
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn’s Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease
Published in Journal of Crohn's and colitis (01-02-2019)“…Abstract Background and Aims There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at…”
Get full text
Journal Article